Larson Financial Group LLC Has $1.09 Million Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Larson Financial Group LLC increased its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 1,649.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 8,749 shares of the biotechnology company’s stock after purchasing an additional 8,249 shares during the period. Larson Financial Group LLC’s holdings in Sarepta Therapeutics were worth $1,093,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of SRPT. Farallon Capital Management LLC raised its position in shares of Sarepta Therapeutics by 102.8% in the 1st quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock valued at $317,630,000 after buying an additional 1,243,427 shares in the last quarter. Principal Financial Group Inc. grew its position in Sarepta Therapeutics by 693.7% in the second quarter. Principal Financial Group Inc. now owns 363,011 shares of the biotechnology company’s stock valued at $57,356,000 after acquiring an additional 317,277 shares during the last quarter. Rhumbline Advisers raised its stake in Sarepta Therapeutics by 146.3% during the second quarter. Rhumbline Advisers now owns 270,941 shares of the biotechnology company’s stock worth $42,809,000 after acquiring an additional 160,942 shares in the last quarter. Blair William & Co. IL grew its stake in shares of Sarepta Therapeutics by 303.7% during the second quarter. Blair William & Co. IL now owns 174,282 shares of the biotechnology company’s stock worth $27,537,000 after buying an additional 131,112 shares during the last quarter. Finally, Retirement Systems of Alabama acquired a new position in shares of Sarepta Therapeutics during the second quarter worth $18,433,000. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Price Performance

Shares of Sarepta Therapeutics stock opened at $114.23 on Monday. The business’s 50-day moving average price is $122.00 and its 200-day moving average price is $131.52. The firm has a market capitalization of $10.91 billion, a PE ratio of 91.38 and a beta of 0.81. Sarepta Therapeutics, Inc. has a 12 month low of $78.67 and a 12 month high of $173.25. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93.

Insider Transactions at Sarepta Therapeutics

In related news, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the sale, the chief financial officer now directly owns 33,946 shares in the company, valued at $4,662,822.56. This represents a 14.99 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 7.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Piper Sandler reduced their price target on Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating on the stock in a report on Thursday, August 8th. William Blair upgraded shares of Sarepta Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Cantor Fitzgerald raised Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $152.00 to $167.00 in a research note on Thursday, November 7th. Robert W. Baird dropped their target price on Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating on the stock in a report on Thursday, November 7th. Finally, StockNews.com lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. Two investment analysts have rated the stock with a hold rating, twenty have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $181.33.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.